Log in or create a free account to read this content
Gain free access to this article, as well as selected content from this journal and more on nature.com
or
References
Jain SH, Powers BW, Hawkins JB, Brownstein JS. The digital phenotype. Nat Biotechnol. 2015;33:462–3.
Marsch, LA (2015). Envisioning the Future: Transformation of HealthCare Systems via Technology. In Marsch, LA, Lord, SE & Dallery, J (Eds.), Behavioral Healthcare and Technology: Using Science-based Innovations to Transform Practice. Oxford University Press, 317–328.
Asch DA, Muller RW, Volpp KG. Automated hovering in health care—watching over the 5000 hours. N Engl J Med. 2012;367:1–3.
Onnela J, Rauch SL. Harnessing smartphone-based digital phenotyping to enhance behavioral and mental health. Neuropsychopharmacology. 2016;41:1691–96.
Barnett I, Torous J, Staples P, Sandoval L. Relapse prediction in schizophrenia through digital phenotyping: a pilot study. Neuropsychopharmacology. 2018. https://doi.org/10.1038/s41386-018-0030-z [Epub ahead of print]
Scherer EA, Ben-Zeev D, Li Z, Kane JM. Analyzing mHealth engagement: joint models for intensively collected user engagement data. J Med Internet Res mHealth UHealth. 2017;5:e1.
Tan X, Shiyko MP, Li R, Li Y, Dierker L. A time-varying effect model for intensive longitudinal data. Psychol Methods. 2012;17:61–77.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
This work was supported by grant P30DA029926 from the National Institute on Drug Abuse, National Institutes of Health (PI: Marsch). In addition to her academic appointment at Dartmouth College, Dr. Marsch is affiliated with several businesses that develop and deploy digital therapeutic interventions. These include HealthSim LLC, Square2 Systems Inc., and Pear Therapeutics Inc. These relationships are extensively managed by Dr. Marsch and her academic institution.
Rights and permissions
About this article
Cite this article
Marsch, L.A. Opportunities and needs in digital phenotyping. Neuropsychopharmacol 43, 1637–1638 (2018). https://doi.org/10.1038/s41386-018-0051-7
Received:
Accepted:
Published:
Issue date:
DOI: https://doi.org/10.1038/s41386-018-0051-7
This article is cited by
-
The comprehensive clinical benefits of digital phenotyping: from broad adoption to full impact
npj Digital Medicine (2025)
-
What patients and caregivers want to know when consenting to the use of digital behavioral markers
NPP—Digital Psychiatry and Neuroscience (2024)